FDA Approves First Interchangeable Biosimilar to Perjeta in HER2+ Breast Cancer
When One Blood Draw Could Tell More: A Look at the Cancerguard Test
FDA Grants Drug Designation to Tinostamustine for Malignant Glioma
FDA Approves Komzifti for NPM1-Mutant Acute Myeloid Leukemia